Phase Ib Feasibility Trial of Neoadjuvant Nivolumab/Lirilumab in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer
Phase of Trial: Phase I
Latest Information Update: 21 Dec 2018
At a glance
- Drugs Lirilumab (Primary) ; Nivolumab (Primary)
- Indications Bladder cancer
- Focus Adverse reactions
- 02 Nov 2018 Status changed from not yet recruiting to recruiting.
- 25 Sep 2018 Planned initiation date changed from 1 Sep 2018 to 1 Oct 2018.
- 25 May 2018 New trial record